ENERGIZE THE FIGHT.
Our Mito Champions
Need to Connect with Us?
Call the Support Line: (888) 900-6486
Your November UMDF Newsletter: Celebrating a TK2d Therapy Approval, MELAS Survey, Mito Books, and More
Signup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup.
FDA Approves First-Ever TK2d Therapy
11/3/25, 5pm EST -- Earlier today, the U.S. Food and Drug Administration (FDA) approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease thymidine kinase 2 deficiency (TK2d). “It’s hard to put into words what today’s decision means for...
SPECIAL NATIONAL AUTHOR’S DAY FEATURE: Mito Patient and His Mom Talk About Self-Publishing “Children’s Chapter Adventure” Book
KSS Patient and Mom Talk About Self-Publishing Their "Children's Chapter Adventure" Book Thomas Gordon is not your typical author. Diagnosed with the mitochondrial disease Kearns-Sayre syndrome in 2014, he lives life totally blind, relies on hearing aids, and cannot...